Neurology

Latest News
February 26th 2025

Adaptive Deep Brain Stimulation Technology Receives FDA Approval for Parkinson Disease

February 14th 2025

Adults With DMD More Than Twice as Likely to Experience Fractures

February 4th 2025

FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease

January 30th 2025

New Model Predicts Stroke Severity and Improves Functional Independence

January 28th 2025

EMBARK 2: Delandistrogene Moxeparvovec Shows Sustained Benefits in DMD

Video Interviews
View All
October 23rd 2024

Future Considerations for Friedreich Ataxia

October 16th 2024

Comorbidities and Complications Associated With Friedreich Ataxia

October 16th 2024

Challenges Associated With Friedreich Ataxia

October 9th 2024

Impact of Friedreich Ataxia on Quality of Life

October 9th 2024

Clinical Utility of the Modified Friedreich Ataxia Rating Scale

October 2nd 2024

Diagnosis of Friedreich Ataxia

October 2nd 2024

Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia

September 11th 2024

Friedreich Ataxia: Looking Forward at the Treatment Landscape

June 26th 2024

Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook

June 26th 2024

Payer Coverage Considerations for New Treatments for Alzheimer Disease

More News

FDA headquarters | Image Credit: Grandbrothers - stock.adobe.com
January 27th 2025

FDA Approves New Maintenance Dosing for Lecanemab to Treat Early-Stage Alzheimer Disease

Brooke McCormick
The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer disease (AD), enabling a transition from biweekly to once-every-4-week dosing while preserving clinical and biomarker benefits.
Heart and stethoscope | Image credit: inthasone - stock.adobe.com
January 24th 2025

Prophylactic Cardiac Medication May Prolong Survival in DMD

Rose McNulty
Prophylactic cardiac treatment may prolong survival in Duchenne muscular dystrophy (DMD), but only one-quarter of individuals received such treatment, a recent study found.
Past studies have explored the association between motor and cardiac function in younger patients with DMD, but there is a lack of research on this relationship as patients with DMD age. | Image credit: Nana_studio - stock.adobe.com
January 13th 2025

Later Loss of Ambulation Linked With Better Heart Health in DMD

Rose McNulty
The results suggest that prolonging ambulation may not adversely impact cardiac function in adulthood for patients with Duchenne muscular dystrophy (DMD).
Patients with MS had higher odds of filling prescriptions for anticonvulsants and higher odds of filling gabapentinoids and gabapentinoids without other anticonvulsants in the years leading up to onset of MS. | Image credit: Vitalii Vodolazskyi - stock.adobe.com
January 6th 2025

Pain May Be Indicator of MS Prior to Disease Onset: Study

AJMC Contributor
Compared with healthy controls, patients with multiple sclerosis (MS) had higher odds of filling prescriptions for gabapentinoids and other anticonvulsants in the 5 years prior to MS onset.
Better understanding the vascular sequelae of MS may similarly unlock predictive insights for people with MS, according to investigators. | Image credit: Elena - stock.adobe.com
January 3rd 2025

Meta-Analysis: Vascular Function Worse in People With MS

Jared Kaltwasser
The differences did not appear to be associated with potential moderating factors like age, sex, or smoking status.
lab test tubes | Image credit: kwanchaift – stock.adobe.com
December 22nd 2024

Study Highlights Trends, Emerging Innovations in DMD Research

Hayden E. Klein
An analysis revealed global trends and emerging focus areas in Duchenne muscular dystrophy (DMD) research, emphasizing the growing impact of precision medicine and gene therapies.
Nurse helping patient use walker | Image credit: LIGHTFIELD STUDIOS – stock.adobe.com
October 9th 2024

Genotypes May Influence When Patients With DMD Have Loss of Ambulation

Hayden E. Klein
A study of 555 patients further solidified genotype-phenotype correlations in Duchenne muscular dystrophy (DMD).
Currently, 4 exon-skipping drugs are FDA approved for DMD: eteplirsen (Exondys 51), golodirsen (Vyondys 53), casimersen (Amondys 45), and viltolarsen (Viltepso) | Image credit: CrazyJuke - stock.adobe.com
September 26th 2024

WVE-N531 Shows Promising Efficacy in DMD at Interim FORWARD-53 Analysis

Rose McNulty
In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
The new results make HERCULES the first and only study to demonstrate reduced CDP in nrSPMS. | Image credit: Juan Gärtner - stock-adobe.com
September 3rd 2024

Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS

Rose McNulty
The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS).
Balance and gait are both important factors in continued mobility among patients with DMD. | Image credit: OlegKachura - stock.adobe.com
August 22nd 2024

Cycling Training Shows Protective Effects on Gait, Balance in DMD

Rose McNulty
Both cycling and home-based exercise training helped maintain gait and balance parameters in children with Duchenne muscular dystrophy (DMD), with cycling training also improving antero-posterior balance.
Results demonstrate correlations between fatigue and walking speed and mobility among patients with multiple sclerosis. | Image credit: kieferpix - stock.adobe.com
Published: August 13th 2024 | Updated: August 14th 2024

Fatigue Linked With Reduced Walking Speed, Mobility in Multiple Sclerosis

Rose McNulty
Study results demonstrated significant correlations between fatigue and reductions in walking speed and mobility among patients with multiple sclerosis.
Healthy behaviors, especially regular exercise and a healthy diet, were associated with better patient-reported outcomes in multiple sclerosis. | Image credit: Daniel Vincek - stock.adobe.com
August 7th 2024

Healthy Lifestyle Behaviors Linked to Better MS Outcomes

Rose McNulty
Engaging with healthy lifestyle behaviors, including a healthy diet and physical activity, was associated with better outcomes among patients with multiple sclerosis (MS).
Blue stamp of FDA approval | Image Credit: argus-stock.adobe.com
June 20th 2024

FDA Grants 2 Approvals to Delandistrogene Moxeparvovec for DMD

Maggie L. Shaw
Accelerated approval was originally granted in June 2023 for patients aged 4 to 5 years, indicating there was an unmet clinical need for a potentially life-saving treatment for the rare genetic muscle disorder.
A panel of 5 experts on Alzheimer disease
June 19th 2024

Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden

Derek van Amerongen, MD, MS Soeren Mattke, MD, DSc B. Joy Snider, MD, PhD Kavita V. Nair, PhD Maria Lopes, MD, MS
An overview of how disease-modifying treatments for Alzheimer disease can impact medical costs and caregiver burden.
A panel of 5 experts on Alzheimer disease
June 19th 2024

Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates

Derek van Amerongen, MD, MS Soeren Mattke, MD, DSc B. Joy Snider, MD, PhD Kavita V. Nair, PhD Maria Lopes, MD, MS
The panel discusses emerging therapies for Alzheimer disease that are currently in development, including donanemab, subcutaneous lecanemab, and ALZ-801.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo